Related Experiment Videos
Metastatic Ewing's sarcoma: remission induction and survival
Summary
This study shows that cyclophosphamide and doxorubicin chemotherapy before surgery and radiation therapy can lead to remission in metastatic Ewing sarcoma. Ten patients remained disease-free for over three years.
Area of Science:
- Pediatric Oncology
- Medical Oncology
- Sarcoma Research
Background:
- Metastatic Ewing sarcoma (ES) presents a significant treatment challenge.
- Optimizing treatment sequencing for metastatic ES is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of a treatment protocol for previously untreated metastatic Ewing sarcoma.
- To assess the response rate to induction chemotherapy followed by delayed surgery, radiation therapy, and maintenance chemotherapy.
Main Methods:
- Eighteen patients with metastatic ES received cyclophosphamide and doxorubicin induction chemotherapy.
- Delayed surgery, lower dose, limited-field radiation therapy (RT), and maintenance chemotherapy were administered.
- Tumor response and long-term disease-free survival were monitored.
Main Results:
- Fourteen of 18 patients achieved remission after induction chemotherapy and delayed surgery.
- Two additional patients achieved complete clinical remission after radiation therapy.
- Primary tumor size at diagnosis influenced outcomes, but metastatic site did not.
Conclusions:
- The combined modality treatment approach shows promise for metastatic Ewing sarcoma.
- Early-stage tumor size is a significant prognostic factor in metastatic ES.
- Long-term disease-free survival was observed in 10 patients, suggesting treatment efficacy.